PRESENTED BY: Andrew Feigin, MD
Clinical Trials for Chorea and Total Functional Capacity
One of the defining symptoms of HD is chorea, which is characterized by abnormal, abrupt, irregular movements. As HD progresses, chorea can become more frequent and severe, negatively impacting quality of life. Maintenance of functional capacity is also a critical unmet need in the treatment of patients with HD. A patient’s functionality is driven by tasks that include the patient’s ability to work, to manage finances, to manage a home, to manage oneself, and to live independently at home. There are two current Phase 3 clinical trials that are evaluating potential new treatments for chorea and functional capacity.
Andrew Feigin, MD
Dr. Feigin is a professor of Neurology at NYU Langone Health and Director of the Marlene and Paolo Fresco Institute for Parkinson’s and Movement Disorders; he also serves as Chair of the Huntington Study Group, a nonprofit dedicated to conducting clinical trials in Huntington disease. Dr. Feigin has been involved in HD research since his participation in the Venezuela Collaborative Research Group, which isolated the HD gene in 1993. His independent research has focused on the development of novel imaging biomarkers that could be used as outcome measures for HD clinical trials. Dr. Feigin is the principal investigator (PI) of the PROOF-HD trial, as well as having served as a study or site PI on numerous other HD trials.